Evidence map›Paper›PMID 37807907›Full record

ArticleJournal of diabetes science and technology2025

Automated Insulin Delivery System and People With Type 2 Diabetes: A Topic With Many Facets.

Lutz Heinemann

Open access · greenAbstract read
In one paragraph

Article in Journal of diabetes science and technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Lutz HeinemannScience Consulting in Diabetes GmbH, Düsseldorf, Germany.ORCID 0000-0003-2493-1304

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Optimizing glucose control is of interest also for patients with type 2 diabetes (T2D). While systems for automated insulin delivery are widely used for patients with type 1 diabetes, as documented by many publications, this is not the case with T2D. Because of the number of such patients, this will change drastically in the next years. Manufacturers can transfer many learnings from type 1 to type 2; however, specific clinical aspects have to be considered. This commentary will discuss these aspects and some of the current activities. Future automated insulin delivery (AID) systems will take data from multisensor systems into account to individualize the AID algorithm, supported by artificial intelligence. There is a high need to document the benefits of AID systems in this patient group.

Indexed as

Diabetes Mellitus, Type 2Hypoglycemic AgentsInsulinInsulin Infusion SystemsAlgorithmsArtificial IntelligenceBlood GlucoseBlood Glucose Self-MonitoringHumansPancreas, ArtificialBlood GlucoseHypoglycemic AgentsInsulinAIDCGMtype 2 diabetes

Identifiers

PMID37807907
PMCPMC11874054
OpenAlexW4387439192

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.